A Single Arm, Open-Label Phase II Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2017
At a glance
- Drugs Nivolumab (Primary)
- Indications Meningioma
- Focus Therapeutic Use
- 15 Nov 2017 Planned End Date changed from 1 Jul 2023 to 1 Dec 2019.
- 15 Nov 2017 Planned primary completion date changed from 1 Jul 2019 to 1 Aug 2018.
- 07 Mar 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.